Laboratory and Clinical Medicine. Pharmacy

Scientific and practical quarterly peer-reviewed journal

 

ISSN 2712-9330 (Online)

VOL 3, No. 1 (2023)

The issue can be purchased
electronic!

PDF format

4000 ₽

Make a request
Share:

    Editorial Article

  • REVIEW OF THE PATHOVIEW ONLINE SERVICE FOR SHARING DIGITAL SAMPLES IN MICROSCOPY

    • Pages: 4-10
    • Views: 243
    The possibility of remote consultations of specialists in microscopy through the exchange of digital preparations is highly important in clinical laboratory diagnostics.
    This review describes the Pathoview online service, which allows storing, viewing and exchanging clinical cases in the form of digital slides in common formats: SVS, TIFF, NDPI, MRXS, DCM. The service requires no additional software installation on your computer or mobile device. In Pathoview, the digital slide is available for viewing in any browser immediately after being uploaded to the service. The link-based sharing function significantly speeds up and simplifies the process of collaborative viewing and remote consultation of specialists.
  • Critical Review

  • ANALYSIS OF THE DRAFT PROFESSIONAL STANDARD “CLINICAL CYTOLOGIST”

    • Pages: 11-18
    • Views: 261
    Clinical cytology is an important component of diagnostic medicine. The purpose is to detect pathological changes at the cellular level. about 3,500 specialists with both higher medical and non-medical education perform cytological studies in our country. Today it is obvious that the growing practical needs of the quantity and quality of cytological studies predetermine the need to optimize the cytological service in Russia.
    To improve cytological diagnostics in Russia a draft professional standard (PS) “Doctor-clinical cytologist” was developed and submitted for public discussion. The article presents the analysis of the draft PS with an objective argumentation of the prematurity and unreasonableness of the adoption and the need for its substantial revision.
  • Original Articles

  • INFORMATIVENESS OF COMBINED HUMAN SEMEN ANALYSIS ON THE WAY TO CLARIFY THE CAUSES OF REPRODUCTIVE DYSFUNCTION: BASIC SEMEN EXAMINATION AND SPERM SEDIMENT CYTOLOGY (SSC)

    • Pages: 19-36
    • Views: 471
    Aim. To analyze the informativeness of combined human semen analysis using a basic semen examination & SSC on the way to clarify the causes of reproductive dysfunction.
    Materials and methods. We examined 529 samples of semen sediment from men aged 18 – 59 years with infertility and male accessory gland infection (MAGI) between 2019 and 2022. Study was conducted in combination of two laboratory methods like ROSE (rapid onesite examination) which one of them is 1 – 'basic semen examination' and second one is 2 – 'SSC' (‘Basic semen examination+SSC’-ROSE).
    Results. 15.13 % of all of patients presented normozoospermia, 1.25 % of them have SSC-markers like bacteriospermia (SSC-mB ?+?). Outcomes of SSC-reports clarify that 84.69 % of all men have the diagnostic significant SSC-findingsand different combination of it; 69.75 % of them were SSC-mB ?+?. ‘Normozoospermia’ and ‘SSC-mB’ are associated, thus, the frequency of SSC-mB in the presence of normozoospermia is recorded as follows.
    Conclusion. The combined approach ‘Basic semen examination+SSC’-ROSE, allows the doctors to exclude a missing in the laboratory algorithm for check-up in male with impaired reproductive function and identifying the causes of idiopathic infertility, the causes of which were mainly positioned as unspecified.
  • Review Articles

  • MORPHOLOGY OF NEUTROPHIL GRANULOCYTES IN NORM AND PATHOLOGY

    • Pages: 37-49
    • Views: 382
    A literature review describing the morphological features of normal neutrophils and their changes in various diseases is presented. Parameters of neutrophil granulocyte nuclei are described, changes in nuclei are characterized in congenital and acquired pathology. The characteristics of the cytoplasm of normal neutrophils and its changes in pathological conditions are also given. Various types of cytoplasmic inclusions present in normal cells and formed in both hereditary and acquired diseases are described in detail. The problems of clinical and diagnostic significance of changes in the morphology of neutrophils are discussed.
  • History of Medicine and Pharmacy

  • THE UNPREDICTABLE HISTORY OF THALIDOMIDE

    • Pages: 50-59
    • Views: 713
    The article reflects the history of thalidomide, synthesized by the West German pharmaceutical company Chemie Gr?nenthal in 1954. Initially the drug was promoted as an effective hypnotic, devoid of the adverse effects of barbiturates. The drug became very popular in Germany and beyond its borders, and had been used in more than 40 countries. At some point thalidomide began to be offered for the treatment of nausea in pregnancy. However with time a gradual increase in the incidence of congenital malformations in children whose mothers took thalidomide during pregnancy was noted. Two doctors – Widukind Lenz and William McBride – are known for drawing public attention to the dangerous consequences of the drug usage in pregnancy. Initially, thalidomide manufacturers denied their guilt, however a numerous number lawsuits obliged pharmaceutical companies to pay huge financial compensations to the victims of thalidomide.
    In the United States, FDA employee Francis Kelsey became famous for not giving permission for thalidomide for the US pharmaceutical market despite its unrestricted usage in European countries. The article provides information about some thalidomide victims who were able to live an active life and become famous. After the recognition of the thalidomide tragedy the therapeutic usage of the drug seemed to be irrevocably terminated. However, in 1964 the Israeli doctor Yakov Sheskin almost by occasion discovered the therapeutic effect of thalidomide on some types of leprosy. In subsequent years the effectiveness of the drug was reported in a number of other diseases. However, the “thalidomide tragedy” with its teratogenicity is still holding back the widespread use of the drug. The bad experience of thalidomide should be a painful lesson for the pharmaceutical industry, but unfortunately, the story can be repeated, that is exemplified by the obesity drug scandal this year.